Naris Nilubol

Dr. Naris Nilubol

Endocrine Surgery Section, Surgical Oncology Program, National Cancer Institute, NIH, Bethesda, MD 20892, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2013 in Thyroid®
Verified
Journal Article
Closed access
Naris NilubolNaris Nilubol
Naris Nilubol
LZLisa Zhang
Lisa Zhang
EKElectron Kebebew
Electron Kebebew
Background: Disparity between the sexes in incidence, disease aggressiveness, and prognosis has been observed in various cancers. Although some investigators have reported that male sex is associated with a worse prognosis in thyroid cancer of follicular cell origin, this finding has not been widely studied and is controversial. Thus, using a large population-based database, we sought to better characterize the role of sex in disease aggressiveness and outcome. Methods: Data of patients with non-medullary thyroid cancer from the Surveillance, Epidemiology, and End Results 17 Registries Database (1988–2007) were used to compare the extent of disease and to analyze the effect of age, sex, race/ethnicity, presence of extrathyroidal extension, lymph node and distant metastases, disease stage, surgical treatment, radiotherapy, tumor size, and histological subtypes on disease-specific survival (DSS) by univariate and multivariate analyses. Results: We identified 61,523 patients with thyroid cancer (female:male=3.5:1). The median follow-up was 54 months. At diagnosis, 61.2% of men were ≥45 years, compared with 49.7% of women ( p <0.01). Men had significantly more aggressive histological subtypes of differentiated thyroid cancer and undifferentiated thyroid cancer, regardless of age group ( p <0.01). Moreover, men had significantly more advanced disease at presentation: larger primary tumor size ( p <0.01), higher rates of extrathyroidal extension ( p <0.01), regional lymph node metastasis ( p <0.01), and distant metastasis ( p <0.01). DSS stratified by pathology was significantly worse in men (227.5 and 234.3 months in men and women, respectively, p <0.01), despite more total thyroidectomies being performed in men ( p 4 cm, extrathyroidal extension, lymph node and distant metastasis, less than subtotal thyroidectomy, and post-operative radiation. Sex was not an independent prognostic factor for DSS. Conclusion: Men with thyroid cancer are more likely to present with more advanced disease, aggressive histological subtypes, and older age. However, sex is not an independent prognostic factor for DSS. Thus, men may benefit from more aggressive screening to detect thyroid cancer at an earlier stage.

25 November 2014 in Cancer
Verified
Journal Article
Open access
PDF file
Naris NilubolNaris Nilubol
Naris Nilubol
EKElectron Kebebew
Electron Kebebew
BACKGROUND: Some centers have advocated selecting patients with small papillary thyroid cancer (PTC) to undergo active surveillance without surgical treatment. The objectives of the current study were to analyze thyroid cancer (TC)‐related mortality in a population‐based cohort and to determine the impact of small PTCs (defined as tumors ≤2 cm in greatest dimension) on TC‐related mortality.METHODS: Data on patients with TC of follicular cell origin from the National Cancer Institute's Surveillance, Epidemiology, and End Results 17 Registries database (1988‐2007) were used to analyze the characteristics of PTCs ≤2 cm in patients who died from TC‐related causes. The effects of clinical features on disease‐specific survival were analyzed.RESULTS: Over the 20‐year study period, the rate of TC‐related mortality was 2.8% (n = 1753 of 61,523 patients). Of the patients who died from TC‐related causes, 38% had PTC, 10% had follicular TC, and 31.3% had anaplastic TC. PTCs ≤2 cm accounted for 12.3% of TC‐related mortalities. Compared with patients who did not experience TC‐related mortality from PTCs ≤2 cm, there were significantly higher rates of men (30% vs 17%;P < .01), patients aged ≥45 years (92% vs 52%;P < .01), tumors measuring >1 cm (59% vs 46%;P < .01), extrathyroid extension (41% vs 11%;P < .01), lymph node metastases (77% vs 28%;P < .01), and distant metastases (31% vs 1%;P < .01) among the patients who died from PTCs ≤2 cm. Independent risk factors for death from PTCs ≤2 cm included age ≥45 years, lymph node and distant metastases, extrathyroid extension, and undergoing less than thyroid lobectomy.CONCLUSIONS: Because 12.3% of patients who experienced TC‐related deaths had PTCs ≤2 cm despite undergoing thyroidectomy, the current results indicate that nonoperative management for patients who have PTCs ≤2 cm should be used with caution. Patients aged ≥45 years with PTCs ≤2 cm should undergo thyroidectomy.Cancer 2015;121:1017–1024.©2014 American Cancer Society.

6 November 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
SLSteven K. Libutti
Steven K. Libutti
LTLawrence Tamarkin
Lawrence Tamarkin
Naris NilubolNaris Nilubol
Naris Nilubol
Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure

9 July 2016 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
Naris NilubolNaris Nilubol
Naris Nilubol
RMRoxanne Merkel
Roxanne Merkel
LYLily Yang
Lily Yang
DPDhaval T. Patel
Dhaval T. Patel
JRJames C. Reynolds
James C. Reynolds
EKElectron Kebebew
Electron Kebebew

3 July 2019 in Cancers
Verified
Journal Article
Open access
PDF file
DMDivya Mamilla
Divya Mamilla
KAKatherine A. Araque
Katherine A. Araque
ABAlessandra Brofferio
Alessandra Brofferio
MGMelissa K. Gonzales
Melissa K. Gonzales
JSJames N. Sullivan
James N. Sullivan
Karel PacakKarel Pacak
Karel Pacak
Pheochromocytomas and paragangliomas (PPGLs) are rare catecholamine-secreting neuroendocrine tumors of the adrenal medulla and sympathetic/parasympathetic ganglion cells, respectively. Excessive release of catecholamines leads to episodic symptoms and signs of PPGL, which include hypertension, headache, palpitations, and diaphoresis. Intraoperatively, large amounts of catecholamines are released into the bloodstream through handling and manipulation of the tumor(s). In contrast, there could also be an abrupt decline in catecholamine levels after tumor resection. Because of such binary manifestations of PPGL, patients may develop perplexing and substantially devastating cardiovascular complications during the perioperative period. These complications include hypertension, hypotension, arrhythmias, myocardial infarction, heart failure, and cerebrovascular accident. Other complications seen in the postoperative period include fever, hypoglycemia, cortisol deficiency, urinary retention, etc. In the interest of safe patient care, such emergencies require precise diagnosis and treatment. Surgeons, anesthesiologists, and intensivists must be aware of the clinical manifestations and complications associated with a sudden increase or decrease in catecholamine levels and should work closely together to be able to provide appropriate management to minimize morbidity and mortality associated with PPGLs.

5 November 2015 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
Naris NilubolNaris Nilubol
Naris Nilubol
LWLee S. Weinstein
Lee S. Weinstein
WSWilliam F. Simonds
William F. Simonds
RJRobert T Jensen
Robert T Jensen
SMStephen J. Marx
Stephen J. Marx
EKElectron Kebebew
Electron Kebebew